Intravenous Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia and Allergy to E. Coli Asparaginase (IND 104224)
Abbreviated List of Eligibility Criteria
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum Tolerated Dose
Each dose level is evaluated
Yes
Heather Grossman, MD
Study Chair
Children's Hopital New York
United States: Food and Drug Administration
T2006-002
NCT00928200
May 2009
June 2010
Name | Location |
---|---|
Johns Hopkins University | Baltimore, Maryland 21205 |
Stanford University Medical Center | Stanford, California 94305-5408 |
Phoenix Children's Hospital | Phoenix, Arizona 85016-7710 |
Childrens Hospital Los Angeles | Los Angeles, California 90027 |
Vanderbilt Children's Hospital | Nashville, Tennessee 37232-6310 |
City of Hope | Duarte, California 91010 |
New York University Medical Center | New York, New York 10016 |
Oregon Health and Science University | Portland, Oregon 97201 |
Seattle Children's Hospital | Seattle, Washington 98105 |
UCSF School of Medicine | San Francisco, California 94143-0106 |
University of Miami Cancer Center | Miami, Florida 33136 |
C.S. Mott Children's Hospital | Ann Arbor, Michigan 48109-0914 |
Childrens Hospital & Clinics of Minnesota | Minneapolis, Minnesota 55404-4597 |
Children's Hospital New York-Presbyterian | New York, New York 10032 |
Miller Children's Hospital | Long Beach, California 90806 |
Children's Memorial | Chicago, Illinois 60614 |
Oakland Children's Hospital | Oakland, California |
University of Minnesota Children's Hospital | Minneapolis, Minnesota |
Nationwide Childrens Hospital | Columbus, Ohio |